Targeted therapies

The three latest SMC decisions will provide new treatment options for some adults with non small cell lung cancer, multiple myeloma and a rare type of lymphoma.

A new targeted treatment has been recommended by the National Institute of Health and Care Excellence for some adults with ovarian cancer.

The Scottish Medicines Consortium (SMC) has approved a new chemotherapy-free treatment option for some adults with untreated chronic lymphocytic leukaemia.

The first chemotherapy-free drug combination for people with a rare type of bowel cancer has been approved for NHS use in England.  

A new combination of targeted treatments will now be available for some adults with leukaemia on the NHS in England.

A new drug that has passed safety tests in adults is likely to be effective against the aggressive childhood cancer neuroblastoma.

A drug combination for people with a rare type of bowel cancer has received an initial rejection from the National Institute for Health and Care Excellence.

The National Institute for Health and Care Excellence has recommended a new combination therapy for adults with an aggressive type of non-Hodgkin lymphoma.

The targeted drug gilteritinib is now recommended for some adults with acute myeloid leukaemia (AML) on the NHS in England.  

New clinical trial results show that adding rituximab to standard chemotherapy could improve survival for some children with non-Hodgkin lymphoma.